Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine in ANCA vasculitis evaluation
2018-001268-40Phase 4Unknown
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and 1 more comparing Hydroxychloroquine adjunctive therapy with Placebo adjunctive therapy (2 arms). Primary endpoint: Percentage of patients with improved active disease control. Status: unknown.
02
Drugs
hydroxychloroquine
03
Conditions
anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)granulomatosis with polyangiitis (GPA)microscopic polyangiitis (MPA)eosinophilic granulomatosis with polyangiitis (EGPA)
Beyond the preview
Go deeper on 2018-001268-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001268-40.